TrialCancer medicine2021

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Ji Hyun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.